. Study Design and Characteristics of Two Phase II Proof-of-Concept Clinical Trials of the pde9 Inhibitor Bi 409306 in Early Alzheimer's Disease. Alzheimer's & Dementia, July 2016, Volume 12, Issue 7S, Part 16, pp820-1. Alzheimers Dement.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. BI 409306